As of June 30, 2023, Pyxis Oncology had cash and cash equivalents and short-term investments of $144.1 million which is expected to fund operations into the first half of 2025 and reflects continued financial discipline.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PYXS:
- PYXS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Pyxis Oncology Reports Financial Results for Second-Quarter 2023 and Provides Corporate Update
- Pyxis Oncology to Present at BTIG Virtual Biotechnology Conference
- Pyxis Oncology initiated with a Buy at EF Hutton
- Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Questions or Comments about the article? Write to editor@tipranks.com